| Literature DB >> 31201586 |
Yewei Jia1,2, Cong Pang3, Kangxian Zhao1,3, Jiawei Jiang1,2, Tan Zhang1,3, Jiaxuan Peng4, Peng Sun1,3, Yu Qian5.
Abstract
Osteoarthritis (OA), which is characterized as a common degenerative joint disease, is presently the most prevalent chronic degenerative joint disease. Accumulating evidence has shown a biological function for Garcinol in a variety of diseases; however, whether it could be used to treat OA remains unclear. In this study, we explored the protective effects of garcinol on the progression of OA and explored the underlying mechanism. In vitro, garcinol reduced the expression of pro-inflammatory cytokines, such as IL-6 and tumor necrosis factor alpha (TNF-α). It also decreased the expression of inducible nitric oxide synthase (iNOS), as well as cyclooxygenase-2 (COX-2). Furthermore, garcinol inhibited the expression of thrombospondin motifs 5(ADAMTS5) and metalloproteinase (MMPs), both of which regulate extracellular matrix degradation. These changes could be attributed to garcinol-related suppression of the IL-1β-induced NF-κB signaling pathway. Moreover, we investigated the protective effects of garcinol on the surgical destabilization of the medial meniscus (DMM) of the mouse, an in vivo model of OA. Taken together, our data suggest garcinol as a potential future agent for the treatment of OA.Entities:
Keywords: DMM; IL-1β; NF-κB; garcinol
Mesh:
Substances:
Year: 2019 PMID: 31201586 DOI: 10.1007/s10753-019-01037-7
Source DB: PubMed Journal: Inflammation ISSN: 0360-3997 Impact factor: 4.092